Jinhe Biotechnology (002688) recently stated in the performance briefing that the market share of its pharmaceutical products produced and sold by its subsidiary in the USA is gradually expanding. The raw materials are the company's use of aureomycin and chlortetracycline, which are currently tariff-free. The company determines that there will be no increase in tariffs. If the USA imposes additional tariffs, most of the increased costs will be transferred to US breeding enterprises. The company will also further expand other overseas markets outside the USA.